【國外Guideline更新】Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

What's New in the Guidelines

Last Updated: November 14, 2017; Last Reviewed: November 14, 2017

The Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States (Perinatal Guidelines) are published in an electronic format that can be updated as relevant changes in prevention and treatment recommendations occur. The Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission (the Panel) is committed to timely changes in this document because so many health care providers, patients, and policy experts rely on this source for vital clinical information.

Major revisions within the last 12 months are as follows:

【國外Guildeline更新】Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

What's New in the Guidelines

Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV Infected Adults and Adolescents document was published in an electronic format that could be easily updated as relevant changes in prevention and treatment recommendations occur.

The editors and subject matter experts are committed to timely changes in this document because so many health care providers, patients, and policy experts rely on this source for vital clinical information.

All changes are developed by the subject matter groups listed in the document (changes in group composition are also promptly posted). These changes are reviewed by the editors and by relevant outside reviewers before the document is altered. Major revisions within the last 6 months are as follows:

【轉知】抗人類免疫缺乏病毒藥品處方使用規範106.09.01

臺灣暴露前口服預防性投藥使用指引

指引下載網站：台灣愛滋病學會

2017 Recommendations for Testing, Managing, and Treating Hepatitis C

原文網址，其他相關內容可參考：Table of Contents | Recommendations for Testing, Managing, and Treating Hepatitis C

(影片) 事前預防性投藥 (PrEP) -- 預防愛滋的新選擇

版權所有：台灣愛滋病學會

臺灣暴露前口服預防性投藥使用指引-臺灣愛滋病學會

Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs Consolidated guidelines

原文網址：WHO | Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs

全文下載：Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs

Consolidated ARV guidelines - second edition, June 2016

原文網址：WHO | Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

全文下載：Consolidated ARV guidelines - second edition, June 2016

CROI 2016 相關資訊網址推薦

HIV & AIDS Information :: CROI 2016


Conference on Retroviruses and Opportunistic Infections (CROI) 2016


CROI Webcasts

2015 STD Treatment (Tx) Guide app

Description

The STD Treatment (Tx) Guidelines mobile app serves as a quick reference guide for doctors and related parties on the identification of and treatment for sexually transmitted diseases (STDs).

The app is a collaboration between CDC's Division of STD Prevention and the Informatics Innovation Unit (IIU) within CDC's Division of Public Health Information Dissemination (DPHID) - Center for Surveillance, Epidemiology and Laboratory Services (CSELS).

These guidelines for the treatment of persons who have or are at risk for sexually transmitted diseases (STDs) were updated by CDC after consultation with a group of professionals knowledgeable in the field of STDs who met in Atlanta on April 30–May 2, 2013. The information in this report updates the Sexually Transmitted Diseases Treatment Guidelines, 2010 (MMWR Recomm Rep 2010;59 [No. RR–12]). These updated guidelines discuss 1) alternative treatment regimens for Neisseria gonorrhoeae; 2) the use of nucleic acid amplification tests for the diagnosis of trichomoniasis; 3) alternative treatment options for genital warts; 4) the role of Mycoplasma genitalium in urethritis/cervicitis and treatment-related implications; 5) updated HPV vaccine recommendations and counseling messages; 6) the management of persons who are transgender; 7) annual testing for hepatitis C in persons with HIV infection; 8) updated recommendations for diagnostic evaluation of urethritis; and 9) retesting to detect repeat infection. Physicians and other health-care providers can use these guidelines to assist in the prevention and treatment of STDs.

APP Download：STD Tx Guide

2015 Sexually Transmitted Diseases Treatment Guidelines

Summary

These guidelines for the treatment of persons who have or are at risk for sexually transmitted diseases (STDs) were updated by CDC after consultation with a group of professionals knowledgeable in the field of STDs who met in Atlanta on April 30–May 2, 2013. The information in this report updates theSexually Transmitted Diseases Treatment Guidelines, 2010 (MMWR Recomm Rep 2010;59 [No. RR–12]). These updated guidelines discuss 1) alternative treatment regimens for Neisseria gonorrhoeae; 2) the use of nucleic acid amplification tests for the diagnosis of trichomoniasis; 3) alternative treatment options for genital warts; 4) the role of Mycoplasma genitalium in urethritis/cervicitis and treatment-related implications; 5) updated HPV vaccine recommendations and counseling messages; 6) the management of persons who are transgender; 7) annual testing for hepatitis C in persons with HIV infection; 8) updated recommendations for diagnostic evaluation of urethritis; and 9) retesting to detect repeat infection. Physicians and other health-care providers can use these guidelines to assist in the prevention and treatment of STDs.
附件下載：2015 STD Treatment Guidelines.pdf

原文轉自：2015 STD Treatment Guidelines

Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV

Overview

This early-release guideline makes available two key recommendations that were developed during the revision process in 2015. First, antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count. Second, the use of daily oral pre-exposure prophylaxis (PrEP) is recommended as a prevention choice for people at substantial risk of HIV infection as part of combination prevention approaches. The first of these recommendations is based on evidence from clinical trials and observational studies released since 2013 showing that earlier use of ART results in better clinical outcomes for people living with HIV compared with delayed treatment. The second recommendation is based on clinical trial results confirming the efficacy of the ARV drug tenofovir for use as PrEP to prevent people from acquiring HIV in a wide variety of settings and populations.

The recommendations in this guideline will form part of the revised consolidated guidelines on the use of ARV drugs for treating and preventing HIV infection to be published by WHO in 2016. The full update of the guidelines will consist of comprehensive clinical recommendations together with revised operational and service delivery guidance to support implementation.

檔案下載：Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV.pdf

原始網址：Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV

Partner agencies support new guideline on antiretrovirals

Mark Dybul, Executive Director, The Global Fund

"We welcome the early release of this guideline. The two recommendations are critically important to moving us towards the fast-track treatment and prevention goals. Expanding access to treatment and prevention, especially for key populations and adolescent girls, is now a major global health challenge that requires our collective commitment and determination. We must embrace ambition if we are going to end HIV as a public health threat.”

Deborah L. Birx, U.S. Global AIDS Coordinator & U.S. Special Representative for Global Health Diplomacy

"PEPFAR applauds the World Health Organization on the release of their ‘Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV.’ This guideline expands life-saving treatment access to all persons living with HIV (PLHIV) and highlights new developments in HIV prevention, including PrEP.‎ These are transformative to epidemic control. Short of an HIV vaccine or cure, this gives us the critical tools we need to create an AIDS-free generation utilizing the FAST TRACK strategy. ‎ We have no excuses - it is up to us to seize this moment and chart a bold course together to end AIDS as a public health threat.‎"

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Revisions to the May 1, 2014, version of the guidelines include key updates to several existing sections and the addition of two new tables. Significant updates are highlighted throughout the document.

Key Updates

The following are key updates to existing sections of the guidelines.

What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient

Since the last version of these guidelines, data from clinical trials and cohort studies, as well as experience in clinical practice, have prompted significant changes to the list of Recommended, Alternative, and Other regimens for treatment-naive patients (Table 6). Additionally, a new table, titled “Antiretroviral (ARV) Regimen Considerations as Initial Therapy Based on Specific Clinical Scenarios,” has been created to guide clinicians on the selection of an initial ARV regimen based on specific clinical scenarios and ARV-related considerations (Table 7).

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

Overview

These are the first World Health Organization (WHO) guidelines for the prevention, care and treatment of persons living with chronic hepatitis B (CHB) infection, and complement similar recently published guidance by WHO on the prevention, care and treatment of infection due to the hepatitis C virus (HCV).

The recommendations in these guidelines promote the use of simple, non-invasive diagnostic tests to assess the stage of liver disease and eligibility for treatment; prioritize treatment for those with most advanced liver disease and at greatest risk of mortality; and recommend the preferred use of nucleos(t)ide analogues with a high barrier to drug resistance (tenofovir and entecavir, and entecavir in children aged 2–11 years) for first- and second-line treatment. Recommendations for the treatment of HBV/HIV-coinfected persons are based on the WHO 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, which will be updated in 2015.

These recommendations provide opportunities to save lives, improve clinical outcomes of persons living with CHB, reduce HBV incidence and transmission, and stigma due to disease, but they also pose practical challenges to policymakers and implementers in low- and middle-income countries.

Guideline 下載：Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection.pdf

原文網站：Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

人類免疫缺乏病毒傳染防治及感染者權益保障條例修正條文 104.1.20

修正緣由：
本次所報修正草案，主要係為就感染者醫療費用給付政策調整回歸健保，及於實務上有增列因醫療之必要性或急迫性得免經受檢人或其法定代理人同意即可採檢之防疫需求，並取消非本國籍感染者入境及停留、居留限制，以符合國際人權趨勢，爰提具本修正案。

資料源自立法院議案關係文書，全文請參考：人類免疫缺乏病毒傳染防治及感染者權益 保障條例部分條文修正草案

轉知—疾病管制署新增修完成「醫療機構因應伊波拉病毒感染之感染管制措施指引」及「個人防護裝備穿脫查檢表」

醫療機構因應伊波拉病毒感染之感染管制措施指引

衛生福利部疾病管制署

2014 年 10 月 27 日 2 版

目的

本份文件提供醫療機構工作人員於照護疑似或確定伊波拉病毒感染病人時參考。文中醫療機

構工作人員係指在醫療機構工作，無論有無給薪，所有可能暴露於病人或感染性物質（包含

身體物質、污染的儀器設備、污染的環境表面、執行醫療處置中引發的咳嗽或呼吸道飛沫微

粒）之人員，例如：醫師、護理師、護理佐理員、醫檢師、放射師、藥師、治療師、技術人

員等醫事專門職業人員、緊急醫療救護服務人員、學生與實習人員、約聘人員、以及未直接

參與醫療照護但可能接觸醫療照護工作人員或病人而具潛在感染風險之人員（如書記、

廚工、清潔人員、警衛、維修人員、掛號人員和志工等）。

全文下載：

http://www.idsroc.org.tw/DB/News/file/332-2.pdf

個人防護裝備穿脫查檢表：

http://www.idsroc.org.tw/DB/News/file/332-3.pdf

英國性病伴侶諮商指引

連結網址：
Revised rapid review of evidence for the effectiveness of partner notification for sexually transmitted infections including HIV

資料來源：http://www.nice.org.uk/

美國AIDS治療指引

美國AIDS治療指引

連結網址：美國AIDS治療指引

參考網址：http://aidsinfo.nih.gov/guidelines